Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has earned a consensus rating of “Hold” from the ten ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $66.25.

A number of analysts have recently commented on the stock. Jefferies Group LLC reissued a “buy” rating and issued a $55.00 price objective on shares of Five Prime Therapeutics in a research report on Monday, May 15th. ValuEngine raised shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, BidaskClub lowered shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd.

Several hedge funds have recently made changes to their positions in the company. Creative Planning raised its position in Five Prime Therapeutics by 0.8% during the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 54 shares in the last quarter. Legal & General Group Plc raised its position in Five Prime Therapeutics by 3.1% during the second quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 287 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Five Prime Therapeutics by 1.9% during the second quarter. The Manufacturers Life Insurance Company now owns 21,449 shares of the biotechnology company’s stock worth $646,000 after acquiring an additional 397 shares in the last quarter. Rhumbline Advisers raised its position in Five Prime Therapeutics by 1.4% during the second quarter. Rhumbline Advisers now owns 34,282 shares of the biotechnology company’s stock worth $1,032,000 after acquiring an additional 484 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. raised its position in Five Prime Therapeutics by 3.0% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,227 shares of the biotechnology company’s stock worth $518,000 after acquiring an additional 494 shares in the last quarter. 84.08% of the stock is currently owned by institutional investors and hedge funds.

Shares of Five Prime Therapeutics (FPRX) traded down 0.24% on Tuesday, hitting $33.64. 53,286 shares of the stock traded hands. The firm’s market capitalization is $941.42 million. The firm’s 50 day moving average is $29.81 and its 200 day moving average is $32.72. Five Prime Therapeutics has a 52 week low of $25.97 and a 52 week high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.15) by $0.43. The business had revenue of $7.80 million during the quarter, compared to the consensus estimate of $8.32 million. Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The business’s revenue for the quarter was down 16.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.49) EPS. On average, analysts expect that Five Prime Therapeutics will post ($5.16) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Brokerages Set Five Prime Therapeutics, Inc. (FPRX) Target Price at $66.25” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/08/brokerages-set-five-prime-therapeutics-inc-fprx-target-price-at-66-25.html.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.